Short answer
Nutex Health Inc. (NUTX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $211M (down 13.6% year over year) with net income of $66M.
Q2 2026 key financials · XBRL
- Revenue
- $211M
- −13.6% YoY · −2.6% QoQ
- Net income
- $66M
- +692.4% YoY · +40.7% QoQ
- Operating margin
- 57.8%
- Gross margin
- 67.0%
- EPS (diluted)
- $9.35
- +565.2% YoY · +43.4% QoQ
Source: XBRL data from the Nutex Health Inc. (NUTX) Q2 2026 10-Q on SEC EDGAR. USD.
Nutex Health Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Arbitration-related costs $(12.5)M vs $48.0M YoY, a $60.5M reduction
- Arbitration fee changes reduced contract services expense by $52.3M
- IDR headwinds: processing backlogs, prolonged timelines, eligibility uncertainty, regulatory changes
- Future court decisions and regulatory changes may adversely affect revenue collection
Risk Factors
- No material change stated overall; new IDR risk tied to No Surprises Act portal modifications
- IDR revenue estimates subject to arbitration outcomes and payer behavior, causing quarterly revenue volatility
- Earn-out dispute over approximately 256,005 shares, including 216,039 ABQ Hospital shares
- Former doctor owners challenge 2024 reverse-split adjustments, creating uncertain dilution or cash settlements
- IDR estimation adjustments may materially affect recognized revenue and stock price performance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nutex Health Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.